Onco Wiki / Indication

Non-small cell lung cancer · line 2 · Docetaxel + Ramucirumab (REVEL) — 2L+ NSCLC post-platinum / post-ICI

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy2
Trackstandard
Linked regimenREG-DOCETAXEL-RAMUCIRUMAB
IDIND-NSCLC-2L-DOCETAXEL-RAMUCIRUMAB
TypeIndication
Statusreviewed 2026-04-25 | pending_clinical_signoff
DiseasesDIS-NSCLC
SourcesSRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025

Notes

STUB — pending Clinical Co-Lead sign-off. Standard-track 2L cytotoxic for driver-negative metastatic NSCLC post-1L chemo+ICI failure. Driver-positive (EGFR, ALK, ROS1, etc.) excluded — those receive next-line targeted TKI. Atezolizumab + bevacizumab + chemo (IMpower150) is alternative bevacizumab-containing 1L; atezolizumab maintenance + sequel cytotoxic options separate Indications.

Used By

Indication